Comments
Novartis says trial results back Tasigna drug
11.12.2012. | ZURICH (Reuters) - Novartis AG's blood cancer drug Tasigna is better at treating a type of chronic myeloid leukemia than its older drug Glivec, according to data from two late-stage trials, boosting prospects for its oncology franchise....
